The European Medicines Evaluation Agency: Open To Criticism

October 02, 1998

(The European Medicines Evaluation Agency: open to criticism)

In an editorial in this week's BMJ Dr Kamran Abbasi, Assistant Editor of the BMJ and Dr Andrew Herxheimer, of the UK Cochrane Centre, argue that the European Medicines Evaluation Agency (EMEA) needs an independent and more thorough system of data collection and appraisal so that doctors and patients can have greater confidence in the drug licensing system. The authors say that the present system of withholding information that is deemed to be commercially confidential (sometimes as little as one per cent of the information about a product that the agency holds, is released into the public domain) strengthens manufacturers' commercial interests at the expense of public confidence.

In the European Union, drugs may be licensed in three ways. The centralised procedure allows applications to be made direct to the EMEA so that drugs can be made available throughout the European Union. Alternatively companies can apply to national licensing authorities, which ensures that product licences granted in one country receive mutual recognition in other member states. Lastly, if a product is to be marketed in a single country, an application can be made to the licensing authority of that country under a national procedure.

Contact:
Dr Kamran Abbasi, Assistant Editor, BMJ, Tavistock Square, London
-end-


BMJ

Related Drugs Articles from Brightsurf:

The danger of Z-drugs for dementia patients
Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.

Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.

Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.

Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.

Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.

New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.

Read More: Drugs News and Drugs Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.